Anyone familiar with my postings know that I am no stock guru. But, I do know the science and the intricacies involved in the FDA application/approval process. So, here is a question, and I invite all input by those savvy in the world of investing:
If (when) Hemaxellerate is approved for trials, since these are not blind trials, which means the information on the success and/or failure of the therapy can be known in as little as 30 days (depending on how the time frame is set up for blood evaluation), if success is showing almost immediately--at least in terms of trials--what can we expect the pps to move to in the short term with such news? Bearing in mind that if such is the case, there will most likely be a vigilant move to proceed with further applications for more treatments.
For anyone wondering there will be an acquisition (those listening to Sierra), nix that thought. Koos has no interest in being acquired--it is his aim to sell each patent/treatment to the highest bidder. Not the company itself. There is much more money in that. Much more.
So, anyone with any thoughts, please enlighten. That means even you ole' pirate!
BMSN
